CeQur funding news – Switzerland-based CeQur has Raised $120M in Funding

The money will be used to grow the sales and availability of CeQur Simplicity, a 4-day wearable insulin delivery device. The company will also expand its sales and clinical teams to help more people with diabetes use this convenient, injection-free device.

CeQur’s new 40,000 sq. ft. cleanroom facility passed all required tests in Q4 2024 and will start making commercial products in 2025. CeQur’s President and CEO, Brad Paddock, said, “We are thankful for our investors' support as we work to improve diabetes care.”

Under Brad Paddock's leadership, CeQur is bringing easy-to-use insulin delivery devices to the market, helping people with diabetes manage their treatment more easily.

It’s product, CeQur Simplicity, is a simple 4-day wearable insulin delivery device that offers convenient, injection-free dosing.

Each CeQur Simplicity patch holds up to 200 units of rapid-acting insulin, given in two-unit doses. It replaces, on average, twelve daily injections over four days.

Research shows that nearly 90% of patients using it Simplicity follow their insulin routine better than those using multiple daily injections.

Read also - VitVio funding news – London-based VitVio has Secured €1.8 Million in Pre-Seed Funding

The patch also helps improve blood sugar control, with patients reaching better A1C and time-in-range goals.

Over 6,000 patients are already using the CeQur Simplicity patch. The company is making it easier for patients with commercial insurance to access the device, with more than two-thirds of them covered.

It has agreements with Medicare Part D and State Medicaid, so over 80% of claims are covered, with an average copayment of under $45 per month.

About CeQur

CeQur is a medical device company focused on making mealtime insulin delivery simpler for people on multiple daily injections. Their product, CeQur Simplicity, is a wearable, easy-to-use insulin delivery device that provides discreet, convenient, and injection-free dosing.